Smacked a good 20% due to no real positive news. Simply hype without confirmation.
- where is FDA acceptance of Volpara technology?
- what happened to the SaaS launch?
- are there major new contracts in the pipeline?
- is expansion on the cards?
Delays are causing investors to bail.
This isn't a PME, but isn't far behind. If a company can keep shares on issue low, it knows how to manage its capital.